Retension Pharmaceuticals, Inc. (NASDAQ:RTSN)
| Market Cap | 45.45M+10.2% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 3.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 88,622 |
| Open | 11.83 |
| Previous Close | 11.32 |
| Day's Range | 11.41 - 12.50 |
| 52-Week Range | 9.66 - 12.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About RTSN
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
$RTSN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in RTSN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RTSN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RTSN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RTSN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RTSN from public contracts
Source: USAspending.gov
RTSN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RTSN’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.